VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
ALZN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
ALZNAlzamend Neuro, Inc.
$1.20$5M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksALZNCash Flow

Alzamend Neuro, Inc. (ALZN) Cash Flow Statement

10Y historyFree accessUpdated daily

Free cash flow remains deeply negative at an outflow of $1.7 million in 2026Q3, highlighting a persistent cash burn that is not supported by any underlying operational revenue.

ALZN Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMApr'25Apr'24Apr'23Apr'22Apr'21Apr'20Apr'19Apr'18Apr'17Apr'16
Cash from Operations-5.96M-6.57M-8.27M-8.92M-6.61M-2.71M-2.35M-1.05M-2.05M-1.42M-18.49K
Operating CF Margin %-----------
Operating CF Growth %-28.49%20.58%7.32%-34.91%-143.88%-15.61%-124.43%49.06%-44.82%-7561.12%-
Net Income-7.04M-4.51M-9.95M-14.88M-12.36M-5.05M-4.41M-4.86M-931.66K-1.57M-69.46K
Depreciation & Amortization95.74K50.74K50.74K23.07K3.55K000000
Stock-Based Compensation164.99K325.11K955.63K3.58M4.41M2.03M1.8M396.17K218.42K114.41K40.98K
Deferred Taxes000-1.71M0000000
Other Non-Cash Items465.14K9.29K7141.71M8.77K454.63K562.28K2.19M227.21K88.47K15.61K
Working Capital Changes356.78K-2.44M670.67K2.35M1.33M-152.45K-299.35K1.23M-1.35M-49.68K-5.63K
Change in Receivables00000000000
Change in Inventory00000000000
Change in Payables1.22M001.71M693.58K000000
Cash from Investing-210K-300K-147.24K0-106.46K100.92K105K234.09K-400K00
Capital Expenditures-210K-300K-147.24K0-106.46K000000
CapEx % of Revenue-----------
Acquisitions00000000000
Investments-----------
Other Investing0000-5.37M100.92K105K234.09K-400K00
Cash from Financing5.52M10.44M3.65M20018.85M4.45M2.29M308.72K2.99M1.42M25.34K
Debt Issued (Net)00300K00400.19K00-364.1K00
Equity Issued (Net)2M1000K1000K0000236.02K1000K00
Dividends Paid00000000000
Share Repurchases00000000000
Other Financing600600020018.85M4.05M2.29M72.7K-259.41K1.42M25.34K
Net Change in Cash-645K3.57M-4.76M-8.92M12.13M1.84M47.68K-502.39K540.02K3.83K6.85K
Free Cash Flow-6.17M-6.87M-8.42M-8.92M-6.72M-2.71M-2.35M-1.05M-2.05M-1.42M-18.49K
FCF Margin %-----------
FCF Growth %13.83%18.4%5.67%-32.78%-147.8%-15.61%-124.43%49.06%-44.82%-7561.12%-
FCF per Share-1.62-15.24-111.97-123.53-101.83-50.40-44.44-23.98-61.02-66.41-
FCF Conversion (FCF/Net Income)0.88x1.45x0.83x0.60x0.54x0.54x0.53x0.21x2.20x0.90x0.27x
Interest Paid00000000000
Taxes Paid00000000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Imminent liquidity and dilution risk

Earnings Quality Lacks Cash Support

According to the provided financial data, ALZN's operating cash flow consistently tracks below net income, with an OCF/NI ratio that fluctuated significantly, reaching 0.79 in 2026Q3, which highlights the absence of any underlying cash-generating capability to offset the company's persistent and deepening net losses.

The disconnect between net income and operating cash flow suggests that the company's reported losses are exacerbated by cash-based operational requirements rather than non-cash accounting adjustments. Investors should monitor this trend, as the inability to bridge the gap between accounting losses and cash burn indicates a structural reliance on external financing.

Persistent Negative Free Cash Flow

As reported in financial statements, ALZN's free cash flow remains deeply negative, with a $1.7 million outflow in 2026Q3, confirming that the firm is in a continuous state of cash depletion as it attempts to fund its clinical development pipeline without any offsetting revenue streams.

The trajectory of free cash flow appears to be dictated entirely by the intensity of R&D activities rather than operational efficiency. This pattern suggests that the company's cash runway is highly sensitive to the pace of clinical trials, leaving little room for error in capital allocation.

Volatile Working Capital Management Trends

Based on reported figures, working capital changes have been highly erratic, swinging from a $269.3K outflow in 2026Q3 to a $269.3K inflow in 2026Q1, which suggests that the company's liquidity is subject to significant quarter-to-quarter fluctuations in payables and accruals as it manages its limited cash reserves.

These swings in working capital may indicate an attempt to manage cash outflows by delaying payments to vendors or clinical sites. Such tactics appear to be a reactive measure to preserve liquidity rather than a sign of efficient operational management.

SBC Masks True Cash Burn

Data from recent filings reveals that stock-based compensation, while declining from $318.3K in 2024Q2 to $9.3K in 2026Q3, has historically served as a non-cash expense that obscures the true magnitude of the company's cash-based operational burn rate during its most critical development phases.

While the reduction in stock-based compensation may appear to improve the quality of earnings, it also removes a mechanism that previously preserved cash. This shift warrants further investigation, as it may force the company to rely more heavily on dilutive equity offerings to cover its ongoing operating expenses.

ALZN — Frequently Asked Questions

Quick answers to the most common questions about buying ALZN stock.

How much cash does Alzamend Neuro, Inc. (ALZN) generate from operations?

Alzamend Neuro, Inc. (ALZN) generated $-6.6M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Alzamend Neuro, Inc.'s free cash flow?

Alzamend Neuro, Inc. (ALZN) reported negative free cash flow of $6.9M in 2025, indicating capital requirements exceeded cash from operations.

What is Alzamend Neuro, Inc.'s capital expenditure (CapEx)?

Alzamend Neuro, Inc. (ALZN) spent $0.3M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.